肝细胞癌(HCC)的诊断与分期:现行指南
本文综述肝细胞癌早期诊断与分期的影像学技术现状。筛查推荐每6个月超声检查,动态MR和/或动态CT的典型血管模式(动脉期强化、静脉期廓清)已获指南认可,敏感度约60%、特异度96-100%。肝胆特异性对比剂、弥散加权序列和PET新示踪剂等仍属研究阶段,尚未纳入循证临床决策。
要点
- HCC典型影像模式为动脉期强化程度高于周围肝(wash-in)及静脉期低密度或低信号(wash-out)。
- 该模式诊断HCC敏感度约60%,特异度96-100%,已获临床指南接受。
- 筛查应基于每6个月一次超声检查。
核心结论
- 影像技术是HCC监测和诊断的关键工具,动态MR和/或动态CT上典型血管模式已获指南认可用于无创诊断;肝胆对比剂MRI、DWI和PET新示踪剂等功能成像仍属研究阶段,尚未纳入循证临床决策。
研究设计与样本
- 综述,总结HCC早期诊断和分期的影像技术现状并讨论最相关的开放问题;原文未报告检索范围与纳入文献。
关键影像表现/征象
- HCC在CT和/或MRI上的典型血管模式为动脉期强化程度高于周围肝(wash-in)。
- 静脉期表现为相对于周围肝的低密度或低信号(wash-out)。
诊断标准与关键数值
- 动态MR和/或动态CT上动脉期强化(wash-in)加静脉期廓清(wash-out)的无创诊断标准已被验证并获临床指南接受。
- 该典型血管模式诊断HCC的敏感度约60%,特异度96-100%。
- 筛查应基于每6个月一次超声检查。
临床应用与阅片要点
- 阅片时按动脉期强化程度高于周围肝(wash-in)和静脉期低密度或低信号(wash-out)的典型血管模式评估HCC。
- 筛查场景为每6个月一次超声检查。
- 肝胆对比剂MRI、DWI和PET新示踪剂目前仍属研究,原文未据此给出纳入日常诊断流程的推荐。
局限性
- 肝胆对比剂MRI、DWI和PET新示踪剂等仍属研究阶段,尚未纳入循证临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
One of the key strategies to improve the prognosis of HCC, beside prevention, is to diagnose the tumor in early stages, when the patient is asymptomatic and the liver function is preserved, because in this clinical situation effective therapies with survival benefit can be applied. Imaging techniques are a key tool in the surveillance and diagnosis of HCC. Screening should be based in US every 6 months and non-invasive diagnostic criteria of HCC based on imaging findings on dynamic-MR and/or dynamic-CT have been validated and thus, accepted in clinical guidelines. The typical vascular pattern depicted by HCC on CT and or MRI consists on arterial enhancement, stronger than the surrounding liver (wash-in), and hypodensity or hyposignal intensity compared to the surrounding liver (wash-out) in the venous phase. This has a sensitivity of around 60% with a 96-100% specificity. Major improvements on liver imaging have been introduced in the latest years, adding functional information that can be quantified: the use of hepatobiliary contrast media for liver MRI, the inclusion of diffusion-weighted sequences in the standard protocols for liver MRI studies and new radiotracers for positron-emission tomography (PET). However, all them are still a matter of research prior to be incorporated in evidence based clinical decision making. This review summarizes the current knowledge about imaging techniques for the early diagnosis and staging of HCC, and it discusses the most relevant open questions.
引用
- Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018. PMID: 29571804. doi:10.1016/j.ejrad.2018.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。